Copyright Reports & Markets. All rights reserved.

Global RNA Interference Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of RNA Interference Therapy by Type
    • 1.3.1 Overview: Global RNA Interference Therapy Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global RNA Interference Therapy Consumption Value Market Share by Type in 2025
    • 1.3.3 siRNA
    • 1.3.4 miRNA
    • 1.3.5 shRNA
    • 1.3.6 piRNA
  • 1.4 Global RNA Interference Therapy Market by Application
    • 1.4.1 Overview: Global RNA Interference Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Cancer Treatment
    • 1.4.3 Hereditary Disease
    • 1.4.4 Infectious Disease
    • 1.4.5 Nervous System Disease
    • 1.4.6 Diseases of Immune System
    • 1.4.7 Cardiovascular Disease
    • 1.4.8 Metabolic Disease
  • 1.5 Global RNA Interference Therapy Market Size & Forecast
  • 1.6 Global RNA Interference Therapy Market Size and Forecast by Region
    • 1.6.1 Global RNA Interference Therapy Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global RNA Interference Therapy Market Size by Region, (2021-2032)
    • 1.6.3 North America RNA Interference Therapy Market Size and Prospect (2021-2032)
    • 1.6.4 Europe RNA Interference Therapy Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific RNA Interference Therapy Market Size and Prospect (2021-2032)
    • 1.6.6 South America RNA Interference Therapy Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa RNA Interference Therapy Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Silence Therapeutics
    • 2.1.1 Silence Therapeutics Details
    • 2.1.2 Silence Therapeutics Major Business
    • 2.1.3 Silence Therapeutics RNA Interference Therapy Product and Solutions
    • 2.1.4 Silence Therapeutics RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Silence Therapeutics Recent Developments and Future Plans
  • 2.2 Arrowhead Pharmaceuticals
    • 2.2.1 Arrowhead Pharmaceuticals Details
    • 2.2.2 Arrowhead Pharmaceuticals Major Business
    • 2.2.3 Arrowhead Pharmaceuticals RNA Interference Therapy Product and Solutions
    • 2.2.4 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Arrowhead Pharmaceuticals Recent Developments and Future Plans
  • 2.3 Janssen Research & Development
    • 2.3.1 Janssen Research & Development Details
    • 2.3.2 Janssen Research & Development Major Business
    • 2.3.3 Janssen Research & Development RNA Interference Therapy Product and Solutions
    • 2.3.4 Janssen Research & Development RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Janssen Research & Development Recent Developments and Future Plans
  • 2.4 Sylentis
    • 2.4.1 Sylentis Details
    • 2.4.2 Sylentis Major Business
    • 2.4.3 Sylentis RNA Interference Therapy Product and Solutions
    • 2.4.4 Sylentis RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sylentis Recent Developments and Future Plans
  • 2.5 Sirnaomics
    • 2.5.1 Sirnaomics Details
    • 2.5.2 Sirnaomics Major Business
    • 2.5.3 Sirnaomics RNA Interference Therapy Product and Solutions
    • 2.5.4 Sirnaomics RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sirnaomics Recent Developments and Future Plans
  • 2.6 Dicerna Pharmaceuticals
    • 2.6.1 Dicerna Pharmaceuticals Details
    • 2.6.2 Dicerna Pharmaceuticals Major Business
    • 2.6.3 Dicerna Pharmaceuticals RNA Interference Therapy Product and Solutions
    • 2.6.4 Dicerna Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
  • 2.7 Alnylam Pharmaceuticals
    • 2.7.1 Alnylam Pharmaceuticals Details
    • 2.7.2 Alnylam Pharmaceuticals Major Business
    • 2.7.3 Alnylam Pharmaceuticals RNA Interference Therapy Product and Solutions
    • 2.7.4 Alnylam Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
  • 2.8 Silenseed
    • 2.8.1 Silenseed Details
    • 2.8.2 Silenseed Major Business
    • 2.8.3 Silenseed RNA Interference Therapy Product and Solutions
    • 2.8.4 Silenseed RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Silenseed Recent Developments and Future Plans
  • 2.9 Vir Biotechnology
    • 2.9.1 Vir Biotechnology Details
    • 2.9.2 Vir Biotechnology Major Business
    • 2.9.3 Vir Biotechnology RNA Interference Therapy Product and Solutions
    • 2.9.4 Vir Biotechnology RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Vir Biotechnology Recent Developments and Future Plans
  • 2.10 OliX Pharmaceuticals
    • 2.10.1 OliX Pharmaceuticals Details
    • 2.10.2 OliX Pharmaceuticals Major Business
    • 2.10.3 OliX Pharmaceuticals RNA Interference Therapy Product and Solutions
    • 2.10.4 OliX Pharmaceuticals RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 OliX Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Bio-Path Holdings
    • 2.11.1 Bio-Path Holdings Details
    • 2.11.2 Bio-Path Holdings Major Business
    • 2.11.3 Bio-Path Holdings RNA Interference Therapy Product and Solutions
    • 2.11.4 Bio-Path Holdings RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Bio-Path Holdings Recent Developments and Future Plans
  • 2.12 Suzhou Ribo Life Science
    • 2.12.1 Suzhou Ribo Life Science Details
    • 2.12.2 Suzhou Ribo Life Science Major Business
    • 2.12.3 Suzhou Ribo Life Science RNA Interference Therapy Product and Solutions
    • 2.12.4 Suzhou Ribo Life Science RNA Interference Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Suzhou Ribo Life Science Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global RNA Interference Therapy Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of RNA Interference Therapy by Company Revenue
    • 3.2.2 Top 3 RNA Interference Therapy Players Market Share in 2025
    • 3.2.3 Top 6 RNA Interference Therapy Players Market Share in 2025
  • 3.3 RNA Interference Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 RNA Interference Therapy Market: Region Footprint
    • 3.3.2 RNA Interference Therapy Market: Company Product Type Footprint
    • 3.3.3 RNA Interference Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global RNA Interference Therapy Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global RNA Interference Therapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global RNA Interference Therapy Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global RNA Interference Therapy Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America RNA Interference Therapy Consumption Value by Type (2021-2032)
  • 6.2 North America RNA Interference Therapy Market Size by Application (2021-2032)
  • 6.3 North America RNA Interference Therapy Market Size by Country
    • 6.3.1 North America RNA Interference Therapy Consumption Value by Country (2021-2032)
    • 6.3.2 United States RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 6.3.3 Canada RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico RNA Interference Therapy Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe RNA Interference Therapy Consumption Value by Type (2021-2032)
  • 7.2 Europe RNA Interference Therapy Consumption Value by Application (2021-2032)
  • 7.3 Europe RNA Interference Therapy Market Size by Country
    • 7.3.1 Europe RNA Interference Therapy Consumption Value by Country (2021-2032)
    • 7.3.2 Germany RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 7.3.3 France RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 7.3.5 Russia RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 7.3.6 Italy RNA Interference Therapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific RNA Interference Therapy Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific RNA Interference Therapy Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific RNA Interference Therapy Market Size by Region
    • 8.3.1 Asia-Pacific RNA Interference Therapy Consumption Value by Region (2021-2032)
    • 8.3.2 China RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 8.3.3 Japan RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 8.3.5 India RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 8.3.7 Australia RNA Interference Therapy Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America RNA Interference Therapy Consumption Value by Type (2021-2032)
  • 9.2 South America RNA Interference Therapy Consumption Value by Application (2021-2032)
  • 9.3 South America RNA Interference Therapy Market Size by Country
    • 9.3.1 South America RNA Interference Therapy Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina RNA Interference Therapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa RNA Interference Therapy Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa RNA Interference Therapy Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa RNA Interference Therapy Market Size by Country
    • 10.3.1 Middle East & Africa RNA Interference Therapy Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia RNA Interference Therapy Market Size and Forecast (2021-2032)
    • 10.3.4 UAE RNA Interference Therapy Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 RNA Interference Therapy Market Drivers
  • 11.2 RNA Interference Therapy Market Restraints
  • 11.3 RNA Interference Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 RNA Interference Therapy Industry Chain
  • 12.2 RNA Interference Therapy Upstream Analysis
  • 12.3 RNA Interference Therapy Midstream Analysis
  • 12.4 RNA Interference Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global RNA Interference Therapy market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    RNA Interference Therapy, or RNAi Therapy, is a cutting-edge medical approach that utilizes small RNA molecules to selectively silence or regulate targeted genes. This therapeutic method involves introducing synthetic small interfering RNA (siRNA) or microRNA (miRNA) into cells, triggering a natural biological process that inhibits the expression of disease-related genes. RNA Interference Therapy shows promise in treating various conditions, including genetic disorders, viral infections, and certain cancers. By leveraging the specificity of RNA molecules, this therapy holds the potential to revolutionize precision medicine by addressing the root causes of diseases at the genetic level, promoting targeted and personalized treatment strategies.
    The RNA Interference Therapy industry is experiencing a dynamic shift towards precision medicine and targeted treatments. Advancements in understanding genetic mechanisms have fueled a surge in RNAi research and development. The trend emphasizes personalized therapies, with a focus on tackling specific gene-related disorders at the molecular level. Improvements in delivery systems, such as nanoparticle technologies, are enhancing the efficiency and specificity of RNA interference. The growing pipeline of RNAi-based drug candidates, especially in oncology and rare diseases, showcases the increasing interest and investment in this therapeutic approach. Overall, the industry trend leans towards unlocking the full potential of RNA Interference Therapy for precise and effective medical interventions.
    This report is a detailed and comprehensive analysis for global RNA Interference Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global RNA Interference Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
    Global RNA Interference Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global RNA Interference Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global RNA Interference Therapy market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for RNA Interference Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global RNA Interference Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Silence Therapeutics, Arrowhead Pharmaceuticals, Janssen Research & Development, Sylentis, Sirnaomics, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Silenseed, Vir Biotechnology, OliX Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    RNA Interference Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    siRNA
    miRNA
    shRNA
    piRNA
    Market segment by Application
    Cancer Treatment
    Hereditary Disease
    Infectious Disease
    Nervous System Disease
    Diseases of Immune System
    Cardiovascular Disease
    Metabolic Disease
    Market segment by players, this report covers
    Silence Therapeutics
    Arrowhead Pharmaceuticals
    Janssen Research & Development
    Sylentis
    Sirnaomics
    Dicerna Pharmaceuticals
    Alnylam Pharmaceuticals
    Silenseed
    Vir Biotechnology
    OliX Pharmaceuticals
    Bio-Path Holdings
    Suzhou Ribo Life Science
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe RNA Interference Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of RNA Interference Therapy, with revenue, gross margin, and global market share of RNA Interference Therapy from 2021 to 2026.
    Chapter 3, the RNA Interference Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and RNA Interference Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Interference Therapy.
    Chapter 13, to describe RNA Interference Therapy research findings and conclusion.

    Buy now